AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)
Description: The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)
Description: The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)
Description: This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)
Description: This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)
Description: In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension.
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)
Description: In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension.
Study NCT04821999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a 940-nm diode laser
Description: a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
Study NCT05389358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asiphephe health worker training
Description: Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours).
Study NCT05389358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asiphephe therapeutic sessions
Description: Asiphephe sessions are manualized using illustrated job aids, a participant workbook, session checklists, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts.
Study NCT05389358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPV assessment
Description: IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none
Study NCT05389358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPV assessment
Description: IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none
Study NCT05389358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral for IPV or Mental Health
Description: Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.
Study NCT05389358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral for IPV or Mental Health
Description: Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.
Study NCT05361746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Plus Adhesive
Description: Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.
Study NCT05361746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scotchbond Universal Adhesive
Description: Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
Study NCT05584657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem etzadroxil/probenecid
Description: Oral sulopenem twice daily for 5 days
Study NCT05584657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: Oral Augmentin twice daily for 5 days
Study NCT05070650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
Study NCT05477641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block
Description: Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
Study NCT04850040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.
Study NCT04850040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.
Study NCT04850040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
Study NCT06435195 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Removal
Description: Resection of pituitary pathologies.
Study NCT06435195 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
Study NCT05272059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Study NCT05070650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 500 mg/10 mg granules for oral solution: one sachet three times per day
Study NCT05070650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 500 mg/10 mg granules for oral solution: one sachet three times per day
Study NCT05070650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 500 mg/10 mg granules for oral solution
Study NCT05070650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 500 mg/10 mg granules for oral solution
Study NCT05592808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Description: Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
Study NCT05592808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Description: Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
Study NCT05592808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Dye Taping
Description: After ESWT application, Low-Dye Taping will be applied 3 times, once a week.
Study NCT05592808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: After ESWT application, Kinesio Taping will be applied 3 times, once a week.
Study NCT05272059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Study NCT05106972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSC infusion
Description: UC-MSC infusion by introvenus
Study NCT05137522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combines with VP-16 and methylprednisolone
Description: Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
Study NCT06252610 — intervention group
Intervention type: DRUG
Intervention: Radiotracer Injection
Description: An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably.
Study NCT06252610 — intervention group
Intervention type: DRUG
Intervention: Contrast Media, Magnetic Resonance
Description: The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected.
Study NCT06252610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes
Study NCT04869579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium (as Selenious Acid)
Description: Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
Study NCT04869579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
Study NCT04772365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819
Description: SHR-1819 will be subcutaneously administered with different dose levels;
Study NCT04772365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered with different dose levels;
Study NCT05477641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca Compartment Block
Description: Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
Study NCT05922267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVE CYCLE OF BREATHING TECHNIQUES
Description: The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~* Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing
Study NCT05922267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION
Description: The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
Study NCT05121077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
Study NCT05474040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine versus multimodal analgesia for post elective craniotomy pain
Description: To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
Study NCT05737030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate
Description: Amino acid combination
Study NCT04864496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prescribe N-acetylcysteine tablets
Description: N-acetylcysteine tablets ,1200 mg two times daily
Study NCT04864496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prescribe placebo tablets
Description: manufactured by Daroo Salamat Pharmed, two times daily
Study NCT05950906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDM608
Description: PDM608 subcutaneous at single or multiple dose(s) assigned by cohort
Study NCT05950906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.
Study NCT05870501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5mg/kg IV infusion
Study NCT05870501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.045mg/kg IV infusion
Study NCT06003751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Low Dose
Description: PER-001 Low Dose Intravitreal Implant
Study NCT06003751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - High Dose
Description: PER-001 High Dose Intravitreal Implant
Study NCT06003751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Sham
Description: PER-001 Intravitreal Sham
Study NCT05033444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV-002
Description: SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated.
Study NCT05033444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
Study NCT05427682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule on Day 1